Needham analyst Michael Matson reiterated a Buy rating on Boston Scientific today and set a price target of $121.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Matson has given his Buy rating due to a combination of factors that highlight Boston Scientific’s potential for sustained growth. The company’s management presented a robust strategy during the 2025 Investor Day, emphasizing their ability to maintain above-average organic growth rates. Their guidance for organic growth exceeding 10% from 2026 to 2028 aligns with expectations and suggests a strong performance outlook.
Key drivers of this growth include innovative products such as FARAPULSE, WATCHMAN, EMPOWER, SEISMIQ, and TIVUS, as well as a strategic focus on higher-growth categories and international expansion. Additionally, Boston Scientific’s projected improvements in operating margins, double-digit EPS growth, and substantial free cash flow yield further support the positive outlook. These elements collectively reinforce the Buy rating, as they indicate a promising trajectory for the company’s financial health and market position.
In another report released yesterday, TD Cowen also reiterated a Buy rating on the stock with a $115.00 price target.
Based on the recent corporate insider activity of 119 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BSX in relation to earlier this year.